Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

FDA Approves Regorafenib for Advanced Colorectal Cancer

September 27th 2012

The FDA has approved regorafenib, an oral multikinase inhibitor, to treat patients with metastatic colorectal cancer whose disease has progressed after prior therapy.

Colonoscopy Linked With Lower Risk of Colorectal Cancer Mortality

August 24th 2012

Colonoscopy is effective for the prevention of colorectal cancer deaths, according to the results of a large, population-based, case-control study.

Regorafenib Extends Survival in Colorectal Cancer, Delays Disease Progression in GIST

August 7th 2012

The oral multikinase inhibitor regorafenib extended OS in patients with metastatic colorectal cancer and improved PFS in patients with gastrointestinal stromal tumors.

FDA Approves Aflibercept for Metastastic Colorectal Cancer

August 3rd 2012

The FDA announced that aflibercept has been approved to treat metastatic colorectal cancer when given in combination with the FOLFIRI chemotherapy regimen.

Research Further Supports Aflibercept Benefit in Metastatic Colorectal Cancer

July 30th 2012

The phase III VELOUR trial demonstrated that the addition of aflibercept to FOLFIRI improved overall survival compared with placebo plus FOLFIRI in patients with metastatic colorectal cancer.

Hereditary Colon Cancer: Which Patients Are at High Risk?

July 16th 2012

Colon cancer is equally as likely as breast and ovarian cancer to be hereditary (approximately 10% of cases, overall) and there are many different genes responsible for these cases.

FDA Approves Cetuximab Plus FOLFIRI for Metastatic Colorectal Cancer

July 10th 2012

The FDA has approved cetuximab in combination with the FOLFIRI regimen as a first-line treatment for patients with mCRC who express EGFR and wild-type KRAS mutations.

Dr. Arnold on Second-Line Avastin Continuation for mCRC

June 19th 2012

Dr. Dirk Arnold, from the University Cancer Center Hamburg, Germany, on Second-Line Bevacizumab Continuation Therapy for Metastatic Colorectal Cancer

Dr. Wood on Family Histories and Genetic Counseling

June 5th 2012

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients

June 3rd 2012

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.

Surgery for Colorectal Cancer Hepatic Metastases Has Little Effect on Health

May 25th 2012

Liver surgery for colorectal cancer hepatic metastases has, for the most part, a minimal and brief negative impact on patient-reported outcomes.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Colonoscopy Recommendation May Cut Adherence to CRC Screening

May 18th 2012

Patients are less likely to complete colorectal cancer screening if their physician recommended colonoscopy rather than recommending fecal occult blood testing.

All Patients With Colorectal Cancer Should Be Genetically Screened

May 7th 2012

Universal tumor testing and a detailed personal and family history assessment are recommended for all patients with newly diagnosed colorectal cancer.

Brivanib Plus Cetuximab Delivers Mixed Results in Colorectal Study

April 16th 2012

Adding brivanib alaninate to cetuximab had no survival advantage over cetuximab alone in patients with KRAS wild-type chemorefractory metastatic colorectal cancer.

Research Backs Anti-EGFR Therapy in mCRC With Wild-Type KRAS

April 13th 2012

New research on predictive and prognostic biomarkers for therapy targeting EGFR strongly suggests that panitumumab should be reserved for mCRC tumors with wild-type KRAS.

Addition of Oxaliplatin to Adjuvant Therapy for Late-Stage Colon Cancer Shows Benefit in Real-World Setting

April 13th 2012

Adding oxaliplatin to conventional chemotherapy increases survival in patients with advanced colon cancer in a broad range of community practice settings.

Many Patients Continue to Smoke After Cancer Diagnosis

April 11th 2012

Being newly diagnosed with lung or colorectal cancer is often not sufficient to motivate cigarette smokers to quit.

Adjuvant Cetuximab Fails to Improve Survival in Colon Cancer

April 3rd 2012

Patients who received cetuximab in combination with a standard adjuvant therapy treatment for colon cancer did not experience improved survival.

Regorafenib Potential Treatment for Metastatic Colorectal Cancer Failing Standard Treatment Options

March 28th 2012

For patients with metastatic colorectal cancer that has progressed on multiple lines of standard therapy, regorafenib may be a new treatment option that achieves disease control.